The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
25k buys are ok...executing immediately...
modest wages
https://gb.wallmine.com/lse/n4p/officer/1673686/nigel-theobald
So far very impressed with his work and great connections.
Appears to be moving up now 7 to 10% up...
Collaboration with MedImmune UK aka Astrazeneca is this still the case
close eye on N4 pharma from Astra then, feels like sng style story
The N4 collaboration with Medimmune/AZ is still in effect, pending Nuvec reaching certain goals which N4 have been racing to achieve. What Medimmune stated at the time was that they would not commit further funds until Nuvec met those goals. Given the substantial advance Nuvec has seen over this last year it is up to the individual to decide if those goals have been met and therefore a reinstatement of Medimmune funding would result but it is certainly a real possibility. In the meantime we know via RNS that Nigel is currently talking to more than one partner.
very informative post
We also know from the full year results we are very well funded now, two and two together, doesn't take a genius to hazard a guess of where we will see the SP soon.
Danbaker, you are right. But in business world when you talk collaboration with others, there is a less chance of success unless somebody is interested and come to you for collaboration!
Everything is *potential* until its a done deal... Its the fact they are in talks with collaboration partners which is huge and with a lot in the news linked to how Nuvec works. Its a hungry investors dream.
Collab with Medimmune is key point
"Danbaker, you are right. But in business world when you talk collaboration with others, there is a less chance of success unless somebody is interested and come to you for collaboration!"
Medimmune showed interest early on and retain the option of progressing the collaboration. We also know from an RNS that Nigel is talking to others. The wording from the RNS states that the data set is being finalized and Nigel is already in talks so the interest is there.
Thanks Danbaker, let us hope that Nigel is successful to have a collaboration with big pharma company who have DNA / RNA vaccines by incorporating Nuvec otherwise money will be down the drain !
“Both of those are approaches which we are beginning to assess.”
It is another indication of a growing momentum towards the creation of vaccines in different forms.
Earlier this month, Nadhim Zahawi, vaccines minister, suggested the Government is assessing “technologies with pills” being developed around the globe.
One such is US-based ImmunityBio which is using UK-developed technology to create vaccines in a pill or tablet form - and has started clinical trials
Before listening to people on here folks listen to the interview with Nigel himself this morning, very good interview in my opinion , We have made huge progress with Nuvec. Lots going on at the moment on the news with oral delivery which is well linked with Nuvec. No wonder its Trade for trade on here.
There is no doubt that the drive to find alternative vaccination methods is being driven by the sheer logistical problems in vaccinating the worlds population by injection which is a huge task for the developed countries let alone 3rd world. This problem is being compounded by the need for multiple injections throughout the year, so in simple terms, the world demands a better solution.
The problem with nasal sprays and pills is getting the vaccine to stay in place long enough to transfect into the cell before being washed away by stomach fluids or nasal mucus. The spikey nature of Nuvec is what allows the particle to stay in place and it is these spikes that are patented and protected from any copying by other companies.
Fantastic news @soundlink. If what you are saying is true its confirmation they are well on their way developing a oral method vaccine, with potential collaborations. No wonder this is shooting up today.
Perfect summation....appreciate that...thanks Dan!
DanBaker:
There is no doubt that the drive to find alternative vaccination methods is being driven by the sheer logistical problems in vaccinating the worlds population by injection which is a huge task for the developed countries let alone 3rd world. This problem is being compounded by the need for multiple injections throughout the year, so in simple terms, the world demands a better solution.
The problem with nasal sprays and pills is getting the vaccine to stay in place long enough to transfect into the cell before being washed away by stomach fluids or nasal mucus. The spikey nature of Nuvec is what allows the particle to stay in place and it is these spikes that are patented and protected from any copying by other companies.
Soundlink.
The research done on pill/nasal vaccination is early stage for most of the companies looking at it and N4 is no exception. However the problem of delivery using this method is as I stated. If N4 can show proof of concept of its oral technology then early stage or not there will be a lot of interest because like Nuvec solves most of the problems associated with the lipid delivery via injection, it also solves the issues with nasal/pill delivery if they get the proof of concept from Evotec.
If Evotec show proof of concept for oral delivery of Nuvec then that will be absolutely huge for the company.
Yes but the two that are in trails.
iosbio tied up with ImmunityBio,, Vaxart doesnt work
9.794p to buy
Yep now 15% up and on the move... might be some news close